Association of CD117 and HLA‑DR expression with shorter overall survival and/or progression‑free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation-Reference-Cited by-同舟云学术

Association of CD117 and HLA‑DR expression with shorter overall survival and/or progression‑free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation

Published:2018-08-24 Issue: Volume: Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Wang Huan¹,Zhou Xin¹,Zhu Jian‑Wei¹,Ye Jian‑Nan¹,Guo Hong‑Feng¹,Sun Chao¹

Affiliation:

1. Department of Hematology, Affiliated Wuxi People's Hospital, Nanjing Medical University, Wuxi, Jiangsu 214023, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High Red Blood Cell Distribution Width to Platelet Ratio is an Independent Poor Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma;Discovery Medicine;2023

2. Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept;International Journal of Molecular Sciences;2022-11-08

3. Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma;Journal of Clinical Medicine;2022-03-25

4. Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis;Hematology;2022-01-24

5. The Prognostic Value of Immunophenotypic Characteristics of Plasma Cells in Newly Diagnosed Multiple Myeloma Patients Treated with First-Generation Proteasome Inhibitor Bortezomib;Clinical oncohematology;2022